Genmab Strategy and Business Model

Executive Overview

Genmab is a Danish biotechnology company focused on discovering, developing, and increasingly commercializing differentiated antibody-based medicines, primarily in oncology and hematology. Founded in 1999 and headquartered in Copenhagen, Genmab built its reputation through antibody engineering platforms such as DuoBody and HexaBody and through a partnering model that let larger pharmaceutical companies fund and scale global launches. That model produced a powerful royalty engine, especially from Darzalex, while newer products such as EPKINLY/Tepkinly and TIVDAK have pushed Genmab further toward a more integrated commercial biotech model. Genmab also has an important non-oncology royalty asset in Kesimpta.

Its footprint is global but not sprawling in the way of a large pharmaceutical manufacturer: Genmab has key operating hubs in Denmark, the Netherlands, the United States, and Japan, while using partners and external manufacturing networks to reach many more markets. As of FY2024, Genmab generated roughly DKK 20 billion in revenue, with economics still led by royalties and collaboration income rather than broad owned-product sales. Strategically, Genmab is trying to convert strong cash generation from legacy partnered successes into a broader pipeline, more product ownership, and a larger role in commercialization.

Genmab at a Glance

Item	Details
Logo
Common name	Genmab
Full legal name	Genmab A/S
Headquarters	Copenhagen, Denmark
Ownership	Public company; widely held institutional ownership with no controlling shareholder publicly evident as of 2024
Ticker	GMAB
Exchange	CPH - Nasdaq Copenhagen
Market Cap	$2.45B
Revenue (FY2024)	$20.80B
Founding / major historical milestones	Founded in 1999; listed in Copenhagen in 2000 and on Nasdaq in the U.S. in 2005; Darzalex first approved in 2015; TIVDAK approved in 2021; EPKINLY/Tepkinly approved in 2023; ProfoundBio transaction announced in 2024
Industry or industries	Biotechnology; antibody therapeutics; oncology and hematology
Key products or services	Antibody therapeutics, partnered royalty products, co-commercialized oncology medicines, antibody platform technologies, drug discovery and development
Geographic footprint	Global, with key operating hubs in Denmark, the Netherlands, the United States, and Japan and partnered commercial reach across major pharmaceutical markets
Business segments as officially reported	One operating and reportable segment
Company website	https://www.genmab.com/

1. What Is the Strategy of Genmab?

Genmab’s public strategy has evolved from being mainly an antibody discovery and licensing company into being a more fully integrated biotech that still partners selectively but wants to keep more downstream economics, commercial experience, and strategic control. The clearest way to understand that strategy is through the Playing to Win framework.

1. 1a. What is the winning aspiration of Genmab?

   Genmab’s winning aspiration is to create differentiated antibody-based medicines that materially improve outcomes for patients with cancer and other serious diseases while building a durable, innovation-led biotech business. In practical terms, winning for Genmab no longer means only discovering molecules and licensing them out early. It means converting its science into multiple commercial products, broadening beyond dependence on a single royalty engine, and proving that its platform technologies can repeatedly generate clinically meaningful drugs.

   Public messaging through FY2024 points to a company trying to become larger in scope and more self-directed: retain more economics on selected assets, commercialize in specialty settings where it has credibility, and use royalty cash flows to fund internal research, development, and external expansion.

2. 1b. Where does Genmab play?

   Genmab plays mainly in specialty biopharma, especially oncology and hematology, with a strong emphasis on antibody therapeutics. It is not trying to be a broad primary-care pharmaceutical company. Its chosen arenas include:

   • Antibody-based medicines, especially monoclonal antibodies, bispecific antibodies, and now antibody-drug conjugates.
   • Cancers and hematologic malignancies where specialist prescribers, biomarker-driven treatment choices, and strong clinical differentiation matter.
   • Selected partnered opportunities outside core oncology, as shown by royalty economics from Kesimpta in multiple sclerosis.
   • Major pharmaceutical markets, especially the United States, Europe, and Japan.
   • Both partnered and selectively self-commercialized products, depending on the asset and territory.

   This is a deliberately narrow field: high-value specialty therapeutics rather than broad, low-price volume markets.

3. 1c. How does Genmab plan to win?

   Genmab plans to win by combining differentiated antibody engineering with selective commercial ambition. The model has three parts. First, it uses proprietary technology platforms to create molecules that can stand out mechanistically or clinically. Second, it partners with large pharmaceutical companies when scale, global infrastructure, or risk sharing are more valuable than full ownership. Third, on newer assets, it seeks to keep more of the economics and customer interface where it believes the market is focused enough for a specialist biotech to compete effectively.

   That creates a hybrid recipe: science-led differentiation, capital-efficient partnering, and selective self-commercialization. In specialty oncology, where treatment centers are concentrated and data matter more than mass promotion, that can be a strong competitive position.

4. 1d. What capabilities must Genmab have in place?

   To execute this strategy, Genmab needs a relatively rare combination of capabilities:

   • Advanced antibody discovery and protein-engineering capabilities.
   • Translational science that links platform biology to clinical hypotheses.
   • Clinical development expertise in complex global oncology trials.
   • Regulatory and safety systems suitable for marketed oncology products.
   • Alliance management, because several major value drivers sit inside partnerships.
   • Commercial, medical affairs, and market-access capabilities in specialty oncology.
   • Manufacturing and Chemistry, Manufacturing, and Controls (CMC) oversight across external networks.
   • Capital allocation discipline, so Darzalex-era cash flows are converted into future assets rather than simply accumulated.

5. 1e. What management systems does Genmab require?

   Genmab needs management systems that are stronger than those of a pure discovery biotech but leaner than those of a global pharmaceutical conglomerate. The critical systems include portfolio governance, stage-gate development reviews, alliance governance with major partners, quality and pharmacovigilance controls, and disciplined capital allocation. It also needs incentive systems that reward long-cycle value creation rather than only near-term milestones.

   Because Genmab reports as one segment, senior management must continually rebalance tradeoffs across internal R&D, business development, commercialization investment, and external manufacturing capacity. That kind of integrated portfolio management is central to whether the strategy succeeds.

2. What Are the Current Strategic Initiatives of Genmab?

As reflected in FY2024 public materials and company communications, Genmab’s most important strategic initiatives are concrete and product-linked rather than abstract.

• Protect and extend the Darzalex royalty base. Darzalex remains the company’s biggest economic engine. Although Johnson & Johnson leads commercialization, Genmab benefits from continued adoption across multiple myeloma regimens, subcutaneous use, earlier-line penetration, and geographic expansion.
• Build EPKINLY/Tepkinly into a larger lymphoma franchise. Epcoritamab is strategically important because it offers Genmab more direct participation in commercial value creation than older royalty-only assets. The company and AbbVie have focused on current approved settings in B-cell lymphomas while pursuing additional studies intended to move the product into earlier lines and broader indications.
• Expand TIVDAK in cervical cancer and adjacent settings. TIVDAK gives Genmab exposure to a marketed antibody-drug conjugate in solid tumors and more commercial operating experience. Post-approval evidence generation and geographic expansion are central to increasing its contribution.
• Advance the next wave of internal pipeline candidates. Genmab continues to invest behind programs emerging from its antibody platforms, including candidates in hematology and solid tumors. The strategic goal is not merely more pipeline volume, but more programs where Genmab has greater ownership and optionality.
• Add new modality depth through ProfoundBio. The announced 2024 ProfoundBio transaction signaled a step-up in Genmab’s antibody-drug conjugate ambitions, especially in solid tumors. It broadened the company’s technology base beyond antibodies alone and strengthened its presence in a modality that has become strategically important across oncology.
• Keep building a fully integrated biotech infrastructure. Genmab has been investing in commercial, medical affairs, regulatory, quality, and market-access capabilities so it can support co-commercialized and future self-led products in selected geographies.
• Use business development selectively rather than indiscriminately. Historically, partnerships have been a major source of value creation. The current strategic posture appears to favor targeted external moves that add platforms, pipeline depth, or strategic rights, not scale for its own sake.

3. What Is the Business Model of Genmab?

Genmab has a hybrid biotech business model. It is neither a classic early-stage biotech living on periodic licensing deals nor a fully self-contained global drug company. Its economics come from a mix of royalties, milestone and collaboration payments, and an increasing contribution from co-commercialized or more directly owned products.

What customers actually buy

There are two distinct buying decisions in Genmab’s model. Pharmaceutical partners buy access to Genmab-discovered molecules, platform technologies, and development collaborations. Healthcare systems, physicians, and treatment centers buy therapies that are meant to improve outcomes in serious diseases. That means Genmab has both a business-to-business model and a specialist biopharma model.

Recurring or repeat-driven versus one-time revenue

Royalties are the most recurring-like part of the model. If a product such as Darzalex or Kesimpta continues to gain patients, move into earlier lines, or remain on therapy longer, Genmab can benefit repeatedly without needing to re-sell the asset. Product sales and profit-sharing economics from commercial-stage assets are also repeat-driven. By contrast, upfront payments and development milestones are inherently lumpy and can make year-to-year revenue less linear.

How pricing power works

Pricing power in Genmab’s world comes mainly from clinical differentiation, not from consumer brand strength. In oncology and immunology, therapies with strong efficacy, survival benefit, or compelling safety and convenience profiles can sustain premium specialty pricing. But Genmab does not always capture that pricing power directly. In partnered products, the commercial partner often sets price and manages access, while Genmab participates economically through royalties or profit share.

Why the business mix matters

The mix between royalty revenue and self-commercialized or co-commercialized revenue is strategically important. Royalty income is attractive because it is high margin and capital light. More direct commercialization can create more upside per asset, but it also brings sales force expense, medical affairs spend, market-access work, and supply-chain complexity. As Genmab keeps more downstream economics, the company becomes less dependent on partners but more operationally complex.

What drives gross margin, operating margin, and cash generation

Gross margin is lifted by royalties, which carry minimal cost of goods sold at Genmab itself. Operating margin then depends heavily on how much the company reinvests in R&D, launch preparation, and commercial infrastructure. Cash generation tends to be strong when royalty streams are large and milestone receipts are healthy, but operating cash flow can be reduced by periods of heavier clinical investment, business development, or acquisition activity.

Revenue model

Genmab’s revenue model includes:

• Royalties on partnered product sales.
• Milestone payments tied to development, regulatory, or commercial events.
• Collaboration and license revenue.
• Reimbursement or shared economics under development and commercialization agreements.
• Growing direct or co-led product economics in selected markets.

4. What Products and/or Services Does Genmab Sell?

Genmab does not have a large traditional services business. Its economic output is medicines, platform-enabled discovery, and collaboration rights.

• Darzalex / Darzalex Faspro (daratumumab). This anti-CD38 therapy for multiple myeloma is Genmab’s most important economic asset. It is commercialized by Johnson & Johnson, and Genmab benefits primarily through royalties. It has been the main driver of Genmab’s scale and cash generation.
• EPKINLY / Tepkinly (epcoritamab). This CD3xCD20 bispecific antibody for B-cell lymphomas is strategically important because it gives Genmab more direct commercial relevance. The product is marketed with AbbVie and represents a meaningful step toward Genmab’s more integrated biotech model.
• TIVDAK (tisotumab vedotin). This antibody-drug conjugate for recurrent or metastatic cervical cancer is important both commercially and strategically. It expands Genmab’s presence in solid tumors and gives it experience in the antibody-drug conjugate space.
• Kesimpta (ofatumumab). Marketed by Novartis for multiple sclerosis, Kesimpta is an important royalty-bearing product even though it sits outside Genmab’s core oncology identity.
• Platform technologies and pipeline assets. Genmab’s DuoBody and HexaBody technologies are not sold like packaged software, but they are commercially valuable because they underpin internal programs and make Genmab attractive as a collaborator. The ADC capabilities added through ProfoundBio expand this platform set further.

The offerings that appear to matter most economically are still Darzalex and other partnered revenue streams. The offerings that matter most strategically are the newer assets and platforms that can reduce long-term reliance on one legacy franchise and increase Genmab’s share of future value.

5. What Are the Key Competitors or Peers of Genmab?

Genmab does not have one simple competitor set because it competes at the level of indications, modalities, and business model. Some companies are direct therapeutic rivals in lymphoma or multiple myeloma; others are closer peers in antibody-centric biotech strategy.

• Roche / Genentech. A major competitor in hematology and oncology biologics, including lymphoma antibodies and bispecifics that compete with EPKINLY/Tepkinly.
• Bristol Myers Squibb. Important in multiple myeloma and hematology, with cell therapy and immuno-oncology assets that compete for similar patients and lines of therapy.
• Gilead / Kite. Particularly relevant in lymphoma, where CAR-T cell therapies can act as substitutes or competitors to bispecific antibody regimens.
• Amgen. A significant player in oncology and T-cell engaging therapies, with experience in bispecific formats and specialist oncology commercialization.
• AstraZeneca. A broad oncology competitor and, through partnerships, an important comparator in antibody and antibody-drug conjugate innovation.
• Merck & Co. Less of a direct antibody-platform peer, but highly relevant because its immuno-oncology combinations shape standards of care across tumors.
• Regeneron. One of the closest business-model peers: a science-led, antibody-centric biotech with strong internal capabilities and selective commercialization.
• argenx. A close European biotech peer in terms of platform science and specialty-biopharma economics, even though its core indications differ.
• BeiGene. A fast-growing global oncology company with growing hematology reach and a willingness to build commercial infrastructure across regions.
• ADC Therapeutics. Relevant especially as Genmab expands into antibody-drug conjugates and solid tumors through ProfoundBio-related capabilities.

One important nuance: some of the largest companies around Genmab are partners rather than direct corporate competitors. Johnson & Johnson, AbbVie, Novartis, and Pfizer are strategically central to Genmab’s economics, even when they compete elsewhere in the market.

6. What Is the Marketing Strategy of Genmab?

Genmab’s marketing strategy is best understood as specialist scientific commercialization, not mass-market pharmaceutical advertising. In oncology and hematology, adoption depends heavily on clinical data, treatment guidelines, key opinion leaders, congress visibility, reimbursement support, and physician confidence in how a therapy fits into increasingly complex treatment pathways.

For older partnered products such as Darzalex and Kesimpta, Genmab’s role in end-market promotion is limited relative to its partners. For more recent products such as EPKINLY/Tepkinly and TIVDAK, Genmab has had stronger reason to invest in medical affairs, market development, field engagement, and launch execution in selected markets. That means its commercial playbook is closer to account-based and specialty-channel marketing than to broad brand advertising.

In practice, Genmab’s marketing emphasis appears to include:

• Scientific communication at oncology and hematology congresses.
• Publication strategy and evidence dissemination.
• Medical affairs engagement with specialist prescribers and treatment centers.
• Payer and health-technology-assessment support where reimbursement pathways matter.
• Launch support and field execution for co-commercialized products.

Marketing is an important capability, but not the core differentiator. Clinical differentiation and market access matter more.

7. What Are the Key Customer Segments of Genmab?

Genmab has a layered customer structure.

• Pharmaceutical partners and licensees. These are among Genmab’s most important economic customers because they fund development, commercialize products globally, and generate royalty streams. This segment includes large-cap pharmaceutical companies that can scale assets beyond what Genmab could do alone.
• Oncologists, hematologists, and specialist treatment centers. These are the core clinical decision-makers for Genmab’s oncology products. Their willingness to adopt a therapy depends on response rates, durability, safety, sequencing, and operational fit.
• Hospitals, infusion centers, specialty pharmacies, and distributor channels. In markets where Genmab is more commercially involved, these entities matter for ordering, distribution, and administration.
• Payers and reimbursement authorities. They are not traditional customers, but they are critical gatekeepers. In specialty biopharma, reimbursement can be as important as physician demand.

By end market, Genmab is still concentrated in oncology and hematology. By revenue economics, it is meaningfully dependent on a relatively small number of major products and partners, with Darzalex remaining the most important contributor.

8. What Is the Sales Model of Genmab?

Genmab effectively has two sales models operating side by side.

• Business development and alliance sales. For many years, a core way Genmab monetized its science was by licensing or co-developing assets with larger pharmaceutical companies. In that sense, one of Genmab’s most important sales motions is not selling pills or vials directly; it is structuring and managing high-value strategic collaborations.
• Specialty-biopharma product sales. For selected marketed assets, Genmab participates more directly through focused commercial teams, particularly in oncology. These teams target specialist prescribers, major treatment centers, and payer stakeholders rather than broad retail channels.

Products typically reach end patients through hospitals, infusion centers, specialty distributors, and partner-led pharmaceutical networks. The channel structure matters strategically. Partner-led sales expand reach and reduce infrastructure needs, but they also limit Genmab’s control over execution and customer intimacy. Direct or co-led commercialization improves learning and upside capture, but it requires more spending and stronger operating discipline.

9. In What Geographies Does Genmab Operate?

Genmab is headquartered in Copenhagen, Denmark, but it is a global company in both development and economics. Its operational footprint is concentrated in a small number of high-value hubs rather than a wide network of owned plants and local subsidiaries.

• Denmark. Corporate headquarters and a key leadership center.
• The Netherlands. An important scientific and development base, especially around antibody research and development activities.
• United States. A major commercial and development hub, with the U.S. also representing the most important pharmaceutical market for many of Genmab’s products.
• Japan. A meaningful commercial and regulatory market where Genmab has built more local presence.

Commercially, Genmab’s reach is much broader than its office footprint because partners market key products across North America, Europe, Asia, and other territories. The company is therefore globally exposed in revenue terms even though it is not fully vertically integrated across manufacturing or local commercial infrastructure.

10. Who Are the Owners of Genmab?

Genmab is a public company and appears to be widely held. No controlling shareholder is publicly evident from the company’s broad market ownership profile as of 2024. Public filings and shareholder disclosures have historically shown a mix of long-term institutional holders, including large global asset managers and, at times, Novo Holdings A/S as a significant shareholder. Because ownership positions change with market trading and filing timetables, the practical takeaway is that Genmab is institutionally owned rather than founder- or family-controlled.

11. How Is Genmab Organized?

At a practical level, Genmab is organized more like an integrated biotech than a diversified pharmaceutical conglomerate. It reports one operating and reportable segment, which suggests management views the business as a single portfolio built on shared science, development capabilities, and commercial infrastructure rather than as separate autonomous divisions.

Operationally, the company appears to be organized around a matrix of:

• Research and discovery.
• Clinical development and regulatory affairs.
• Commercial, medical affairs, and market access.
• Technical operations and CMC oversight.
• Alliance management for partnered assets.
• Corporate functions such as finance, legal, and business development.

That structure fits Genmab’s model: a relatively focused portfolio company where value is created by moving programs across stages while balancing internal assets and partnered programs under one senior leadership team.

12. How Does Genmab Operate?

Genmab operates by moving antibody-based assets from discovery into development, then either partnering them, co-developing them, or participating in commercialization. Day to day, that means target selection, antibody engineering, translational biology, trial design, patient enrollment, regulatory interactions, manufacturing oversight, safety monitoring, and commercial planning.

The operational model is specialized rather than vertically broad. Genmab does not need to own a giant manufacturing estate to create value. Instead, it combines internal scientific and strategic control with external partners, contract manufacturers, and commercial collaborators. Its biggest operational complexities include:

• Running global oncology and hematology clinical programs.
• Coordinating with partners that may control different rights by product or territory.
• Managing biologics and ADC manufacturing quality across external networks.
• Building commercial capabilities without bloating the organization.
• Balancing short-term revenue strength with long-cycle R&D investment.

In effect, Genmab is an orchestration business built on science: it creates value by selecting the right molecules, designing the right trials, and choosing where to partner versus where to keep more control.

13. What Are the Growth Opportunities for Genmab?

Genmab’s most plausible growth opportunities are visible in both management’s stated priorities and the logic of its portfolio.

• More value from Darzalex. Even though Darzalex is mature relative to newer assets, continued regimen expansion and broad global penetration can still support royalty growth.
• EPKINLY/Tepkinly expansion. Moving epcoritamab into earlier lines of therapy or additional lymphoma settings is one of the clearest drivers of medium-term upside.
• TIVDAK growth. Additional uptake in cervical cancer, potential regimen expansion, and broader geographic commercialization can increase its contribution.
• Pipeline maturation from internal platforms. The more Genmab can convert DuoBody, HexaBody, and other scientific capabilities into differentiated late-stage assets, the less concentrated the company becomes.
• Antibody-drug conjugates and solid tumors. The ProfoundBio move suggests Genmab sees meaningful long-term growth in ADCs and in expanding beyond its historical hematology strength.
• More selective self-commercialization. In focused specialty markets, Genmab may be able to capture more economics by building its own commercial presence rather than out-licensing too early.
• Partnerships and business development. New collaborations remain a credible source of non-dilutive growth, especially where Genmab’s platform technologies solve problems for larger pharmaceutical companies.

The main constraints are also clear: clinical trial risk, intense competition in hematology and oncology, reimbursement pressure, manufacturing complexity for biologics and ADCs, and the challenge of diversifying a business still strongly shaped by Darzalex economics.

14. What Is the History of Genmab?

Genmab was founded in 1999 in Denmark as a human-antibody biotechnology company, with early roots tied to antibody technology associated with Medarex. Its early years were focused on building a scientific platform and proving that high-value antibody discovery could be developed into a durable biotech business.

• 1999: Genmab was founded in Denmark.
• 2000: The company listed on the Copenhagen stock exchange, giving it public-market access early in its life.
• 2005: Genmab added a U.S. Nasdaq listing, broadening its investor base.
• 2009: Arzerra became an early approved antibody product and demonstrated the company’s ability to generate clinically relevant assets.
• 2012: The daratumumab collaboration with Janssen marked a pivotal strategic event.
• 2015: Darzalex received its first approval, fundamentally changing Genmab’s economics and turning the company into a major royalty beneficiary.
• 2021: TIVDAK added a marketed oncology product with more direct commercial relevance.
• 2023: EPKINLY in the U.S. and Tepkinly in Europe marked another step toward Genmab’s more integrated commercial model.
• 2024: The announced ProfoundBio transaction signaled a deeper move into antibody-drug conjugates and solid tumors.

The broad historical arc is clear: Genmab began as an antibody discovery company, proved the value of partnering, then used the success of Darzalex to finance a transition toward a broader, more self-directed biotech model.

15. How Does the Supply Chain of Genmab Function?

Genmab’s supply chain is important, but it is not organized like that of a large, fully integrated pharmaceutical manufacturer. The company creates most of its strategic value in discovery, development, and portfolio control, while much of the physical supply chain is handled through partners and external providers.

The main supply-chain activities include:

• Process development and scale-up for biologics and antibody-drug conjugates.
• Drug substance and drug product manufacturing, often through external networks.
• Fill-finish, quality release, and regulatory documentation.
• Clinical trial supply planning across multiple countries and studies.
• Cold-chain and specialty distribution for commercial products.
• Coordination with partners that hold commercialization rights in many markets.

Supply-chain reliability matters strategically because oncology launches can be constrained by manufacturing bottlenecks, comparability work, quality events, or limited ADC capacity. For Genmab, strong CMC oversight and partner coordination are therefore critical even if the company does not own most of the physical infrastructure.

16. What Are the Key Assets of Genmab?

Genmab is not especially asset-heavy in terms of owned factories or distribution depots. Its most important assets are scientific, intellectual, contractual, and financial.

• The Darzalex royalty stream. This is one of Genmab’s most valuable economic assets because it funds the rest of the portfolio.
• Platform technologies. DuoBody and HexaBody are core strategic assets because they create both internal pipeline value and external partnering leverage.
• Clinical and commercial rights in newer products. EPKINLY/Tepkinly and TIVDAK matter because they increase future value capture and commercial learning.
• Pipeline candidates and associated clinical data. In biotech, differentiated data packages are often more valuable than physical infrastructure.
• Intellectual property. Patents, know-how, and antibody engineering expertise are central barriers to entry.
• Partner relationships. Deep ties with major pharmaceutical companies are real strategic assets because they affect funding, speed, and global reach.
• Cash generation and liquidity. A strong balance sheet is a competitive asset in biotech because it allows continued R&D investment without depending constantly on external financing.

17. What Is the Technology Strategy of Genmab?

Technology is central to Genmab’s competitiveness. The company’s strategy is not simply to run more clinical trials than peers; it is to use proprietary antibody engineering platforms to create molecules that are harder to replicate and more likely to show differentiated clinical behavior.

Its technology strategy appears to have four elements:

• Platform-first innovation. Genmab’s antibody technologies are intended to be repeatable engines for creating multiple products, not one-off inventions.
• Internal and external monetization. The same technology can support Genmab-owned pipeline programs and collaboration deals with large pharmaceutical companies.
• Modality expansion. The move into antibody-drug conjugates through ProfoundBio broadens Genmab from antibody engineering into a wider oncology-technology stack.
• Technology tied to clinical strategy. Genmab’s platforms are most valuable when paired with good target selection, translational biology, and smart indication sequencing.

In Genmab’s case, technology is both an internal enabler and a commercial asset. That is a major reason the company can generate value even before a product is fully commercialized.

18. What Is the R&D Strategy of Genmab?

R&D is the core of Genmab’s identity. The company’s strategy is to invest in differentiated antibody-based innovation where platform science, target biology, and clinical design can create a meaningful edge. That generally means oncology and hematology programs in settings where specialist physicians will adopt new therapies if the evidence is compelling.

Several features define the R&D approach:

• Focus on differentiated mechanisms. Genmab is not trying to fill a portfolio with undifferentiated follow-ons.
• Use platform science repeatedly. R&D productivity depends on turning core technologies into multiple shots on goal.
• Balance partnered and proprietary programs. Partnerships reduce risk and add reach, while proprietary programs preserve more upside.
• Push successful assets deeper into treatment pathways. Once proof of concept exists, the value-creation challenge becomes lifecycle expansion into more lines or indications.
• Add new modalities where scientifically justified. The ADC move suggests Genmab wants a broader toolkit, not just more of the same antibody formats.

The main R&D challenge is portfolio discipline. In a strong-cash biotech, the temptation is to fund too many programs. Genmab’s returns will depend on whether it continues to select only those assets with a credible path to clinically and commercially meaningful differentiation.

19. What Is the Finance Strategy of Genmab?

Genmab’s finance strategy is built around an unusual advantage for a biotech: strong royalty-driven cash generation. That allows the company to fund internal R&D, support launch investments, and pursue selective business development without relying as heavily on new equity issuance as many biotechnology peers do.

At a high level, the company’s financial strategy appears to prioritize:

• Reinvesting royalty cash flows into future growth. Darzalex-generated economics help finance the broader pipeline.
• Maintaining strategic flexibility. A strong liquidity position supports long development cycles and reduces financing risk.
• Funding commercialization selectively. Genmab can choose where to build its own capabilities rather than commercialize everything itself.
• Using external transactions where the strategic logic is strong. The ProfoundBio move fits this logic.

Finance also intersects with strategy through business mix. Royalty revenue is highly attractive from a margin and cash-conversion standpoint, but long-term valuation likely depends on whether Genmab can turn today’s cash engine into a more diversified portfolio of owned or co-owned products. Foreign-exchange management also matters because the company reports in Danish kroner while much of biotech deal activity, partner revenue, and cost exposure is global.

20. What Major Acquisitions Has Genmab Made?

Historically, acquisitions have not been the primary way Genmab built value. The company has been much more partnership-driven than roll-up-driven. Its most important historical moves have often been collaborations, licensing agreements, and co-development structures rather than large takeovers.

The standout recent exception is the announced 2024 acquisition of ProfoundBio, a transaction valued at approximately $1.8 billion when announced. Strategically, that deal mattered because it added antibody-drug conjugate capabilities and expanded Genmab’s exposure to solid tumors. It also showed that Genmab was willing to use its balance sheet more aggressively when an external asset could materially accelerate its modality breadth.

That distinction matters. Genmab’s stated and observed behavior suggests M&A is a selective capability-building tool, not the default growth engine. The company has generally preferred to partner broadly and acquire sparingly.

21. How Companies Like Genmab Leverage Independent Consultants through Umbrex

Umbrex has grown a global community of over 8,000 independent management consultants based in more than 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top consulting firms. Companies like Genmab engage Umbrex when they need talent with the training these top global firms provide but do not need a full team with all the overhead. Umbrex consultants work across Strategy, Operations, Organization, Marketing, Sales, Finance, Technology, ERP, and AI. For a company with Genmab’s mix of partnered products, internal pipeline, specialty commercialization, and selective M&A, the most relevant projects tend to be highly targeted and execution-oriented.

• Portfolio prioritization across royalty-funded internal programs, including scenario-based capital allocation for hematology, solid tumor, and ADC assets.
• Commercial strategy diagnostics for EPKINLY/Tepkinly and TIVDAK, including account segmentation, field-force sizing, and launch-execution improvement.
• Post-acquisition integration support for a transaction like ProfoundBio, including integration management office design, decision-rights mapping, and milestone tracking.
• Market opportunity assessments for new indications, earlier-line expansion strategies, and geography prioritization for specialty oncology assets.
• Alliance-governance redesign for complex co-development and co-commercialization relationships with large pharmaceutical partners.
• Clinical-operations process improvement, including trial-site selection, enrollment acceleration, and development PMO support.
• End-to-end CMC and supply-chain resilience reviews for biologics and antibody-drug conjugates managed through external manufacturing networks.
• Pricing, reimbursement, and market-access strategy for specialty oncology launches in the U.S., Europe, and Japan.
• SG&A productivity and operating-model work as Genmab scales from a royalty-rich biotech into a broader commercial organization.
• AI and advanced-analytics roadmap projects for clinical development, medical affairs insight generation, competitive intelligence, and commercial planning.